We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Dengue Virus IgG Rapid Diagnostic Test Evaluated

By LabMedica International staff writers
Posted on 16 Jun 2021
Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. More...
Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

The virus has five serotypes; infection with one type usually gives lifelong immunity to that type, but only short-term immunity to the others. Subsequent infection with a different type increases the risk of severe complications. A number of tests are available to confirm the diagnosis including detecting antibodies to the virus or its RNA.

Scientists at Sanofi Pasteur (Lyon, France) tested their novel lateral flow immunoassay, OnSite Dengue immunoglobulin G (IgG) on blood samples that had been archived from participants aged 6 to 16 years in two phase three trials. Each serum sample was first tested using a plaque reduction neutralization test (both PRNT90 and PRNT50 levels) and an IgG ELISA for anti-nonstructural protein 1 (anti-NS1) to establish the baseline (pre-vaccination) dengue virus serostatus. A total of 346 blood samples tested seronegative for the dengue virus.

The investigators used all of these seronegative samples to evaluate the specificity of the rapid diagnostic test, and the results showed a specificity of 98.0%. For sensitivity, a random subset of 233 blood samples that were seropositive for dengue virus were used. The sensitivity of the rapid diagnostic test to be able to identify previous dengue virus infection status was found to be 95.3%.

Cross-reactivity of the rapid diagnostic test to Flaviviruses other than the dengue virus was also tested. For each type of Flavivirus tested, the samples used were seronegative for dengue virus but seropositive for the Flavivirus on a neutralization test or IgG ELISA, or the participant’s records showed prior vaccination against the Flavivirus. For this group, the rapid diagnostic test was found to be cross-reactive for the yellow fever virus in one blood sample (one cross-reactivity out of 42 samples that were seropositive for the yellow fever virus; 2.4%) and for Japanese encephalitis virus in one blood sample (1/36; 2.8%). For the blood samples displaying previous exposure to Zika virus (0/35) and the West Nile virus (0/32), the novel rapid diagnostic test had zero cross-reactivity.

Yasemin Ataman-Önal, PhD, from Sanofi Pasteur, said, “These findings support the use of this first-in-class point-of-care test to determine dengue serostatus and eligibility for dengue vaccination and because the tetravalent dengue vaccine is only indicated only for people who have had prior infection with the virus, pre-vaccination screening is necessary.” The study was presented at the Virtual 39th Annual Meeting of the European Society for Pediatric Infectious Diseases held 24-29 May, 2021.


Related Links:
Sanofi Pasteur


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.